| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77299SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NBP1-42761 | |||
| HRP | NBP1-42762 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB600-1131SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-683-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-39002SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-56726 | |||
| BSA Free | NB100-56722SS | |||
| Azide and BSA Free | NB100-56726SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56509SS | |||
| Azide and BSA Free | NBP2-80788 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19371SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24917SS | |||
| Azide and BSA Free | NBP2-77073 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-80652-0.1mg | |||
| BSA Free | NB100-77417SS | |||
| Azide and BSA Free | NBP2-80652 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24787SS | |||
| Azide and BSA Free | NBP2-80981 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NLS1878AF405 | |||
| Alexa Fluor 488 | NLS1878AF488 | |||
| Alexa Fluor 647 | NLS1878AF647 | |||
| Alexa Fluor 700 | NLS1878AF700 | |||
| Biotin | NLS1878B | |||
| DyLight 405 | NLS1878V | |||
| DyLight 488 | NLS1878G | |||
| DyLight 550 | NLS1878R | |||
| DyLight 650 | NLS1878C | |||
| FITC | NLS1878F | |||
| HRP | NLS1878H | |||
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0014.jpg "Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.")
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Mouse Cell lines. 15 ug of lysates per lane. Antibodies: [NBP1-77299], (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Observed molecular weight ~50 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0022.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis using RIPK3/RIP3 antibody [NBP1-77299]. L929 cell line (mouse). 20 ug whole cell lysate. Primary antibody: 1:2000. Secondary antibody: 1:20000. Western blot image submitted by a verified customer review. Observed molecular weight ~57 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0024.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - C2C12 Cells. 15 ug of lysates per lane. Antibodies: RIPK3/RIP3 antibody [NBP1-77299], 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: NBP1-77299, 0.1 ug/mL in the presence of peptide blocking. Lane 2: NBP1-77299, 0.1 ug/mL Lane 3: NBP1-77299, 0.2 ug/mL Lane 4: NBP1-77299, 0.5 ug/mL. Observed molecular weight ~55 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0021.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Bone-marrow-derived macrophages exhibit significant reduction in RIPK3 levels in Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre mice. (A,B) BMDMs were isolated, differentiated on chamber slides for 7 days, immunostained for macrophage markers CD68 (red; A) & CD11b (pink; B), & co-stained for nuclei (Hoechst; blue). All cells from seven separate BMDM isolations were positive for these markers (n=7). (C) A phagocytosis assay was performed on BMDMs with fluorescent polystyrene beads. Phagocytic cells display TRITC+/Hoechst+ signal, & 85% of cells from two separate BMDM isolations were double positive (n=2). (D-F) Protein or RNA was collected from control, Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre BMDMs. RNA was converted to cDNA & analyzed by qPCR for Ripk3 levels (D). Protein lysates were immunoblotted to identify CD11b, RIPK3 & beta -actin (loading control) (E) & quantified (F). (G) RNA from control & Ripk3 delta Global BMDMs was converted to cDNA & analyzed by qPCR for Ripk3-Exon 10 levels. For panels D,F,G, each dot represents a BMDM isolation from an individual animal. Statistics for panels D & F were calculated using one-way ANOVA with Dunnett's multiple comparisons test. Overall ANOVA P-values (prior to the post hoc tests) are 0.0002 (D) & 76%. Values are expressed as means +/- SEM; * p 76%. Values are expressed as means +/- SEM; * p < 0.05 versus WT group; #p < 0.05 versus WT-I/R group, (n = 6/group). (D) Graph showing increases in the levels of serum creatine in WT mice after renal I/R compared to sham-operated animals. However, in RIP3−/− mice, the level of serum creatine was reduced when compared to littermate WT mice after renal I/R. Note that there was no difference in the levels of serum creatine between WT and RIP3−/− sham mice. Values are expressed as means +/- SEM; * p < 0.05 versus WT-Sham group, respectively; #p < 0.05 versus WT-I/R group (n = 6/group). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35741025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-knockout-validated-132202618215124.jpg)
![Western Blot: IL-6 Antibody [NB600-1131] - Western Blot: IL-6 Antibody [HRP] [NBP1-42762] - Lane 1: Human IL-6. Lane 2: none. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Peroxidase Human IL-6 secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 20 kDa for Human IL-6. Other band(s): none. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/IL-6-Antibody-Western-Blot-NB600-1131-img0014.jpg "Western Blot: IL-6 Antibody [NB600-1131] - Western Blot: IL-6 Antibody [HRP] [NBP1-42762] - Lane 1: Human IL-6. Lane 2: none. Load: 50 ng per lane. Primary antibody: none. Secondary antibody: Peroxidase Human IL-6 secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 20 kDa for Human IL-6. Other band(s): none. Image using the HRP form of this antibody.")
![Immunohistochemistry: IL-6 Antibody [NB600-1131] - GBM ECs express IL-6. Mouse GBM was induced by orthotopic injection of GL26 glioma cells into wild-type mouse. The brain sections that include normal brains and tumors were stained with anti-CD31, anti-IL-6, and anti-CSF-1 antibodies. Representative immunofluorescence images are shown. Right, enlarged area in normal and tumor tissues. Bar represents 50?um. Zoom-in factor: 4 Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-03050-0) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-6-Antibody-Immunocytochemistry-Immunofluorescence-NB600-1131-img0015.jpg)
![Western Blot: IL-6 Antibody [NB600-1131] - Protein was resolved on a 4-20% Tris-Glycine gel by SDS-PAGE and transferred onto nitrocellulose. The blot shows detection of a band 21 kDa in size corresponding to anti-IL6 antibody. Molecular weight markers are also shown (MW). After transfer, the membrane was blocked for 30 minutes with 1% BSA-TBST. Detection occurred using peroxidase conjugated anti-Rabbit IgG secondary antibody diluted 1:40,000 in blocking buffer for 30 min at RT followed by reaction with FemtoMax chemiluminescent substrate.](http://images.novusbio.com/fullsize/IL-6-Antibody-Western-Blot-NB600-1131-img0013.jpg)
![Immunocytochemistry/ Immunofluorescence: IL-6 Antibody [NB600-1131] - GBM ECs express IL-6. a Human brain ECs were treated with glioma-CM for 24 h, & cell lysates were subjected to multiplex cytokine array analysis. Left, a representative blot. Right, quantified dot intensity of most significantly changed cytokines. b Human microvascular brain ECs were treated with glioma-CM that were harvested from different human glioma cells. Cell lysates were immunoblotted. c Human microvascular brain ECs & tumor-associated ECs isolated from different GBM patients were subjected to immunoblot analysis. d Mouse GBM was induced by orthotopic injection of GL26 glioma cells into wild-type mouse. The brain sections that include normal brains & tumors were stained with anti-CD31, anti-IL-6, & anti-CSF-1 antibodies. Representative immunofluorescence images are shown. Right, enlarged area in normal & tumor tissues. Bar represents 50 μm. Zoom-in factor: 4 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29422647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-1131_rabbit-polyclonal-il-6-antibody-310202416154648.jpg)
![Immunohistochemistry: CD68/SR-D1 Antibody (KP1) [NB100-683] - Representative images (40x) of infiltrated macrophages stained with anti-CD 68 in the gingiva. The black arrowheads indicate the infiltrated macrophages. The right graphs show the quantitative data of CD68-positive cells in HPF (magnification of 200x). Data are expressed as the mean +/- SEM of three slides. *p<0.05 compared with control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0102450) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunohistochemistry-NB100-683-img0009.jpg "Immunohistochemistry: CD68/SR-D1 Antibody (KP1) [NB100-683] - Representative images (40x) of infiltrated macrophages stained with anti-CD 68 in the gingiva. The black arrowheads indicate the infiltrated macrophages. The right graphs show the quantitative data of CD68-positive cells in HPF (magnification of 200x). Data are expressed as the mean +/- SEM of three slides. *p<0.05 compared with control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0102450) licensed under a CC-BY license.")
![Flow Cytometry: CD68/SR-D1 Antibody (KP1) [NB100-683] - An intracellular stain was performed on THP-1 cells with CD68/SR-D1 Antibody NB100-683 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1:50 for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Flow-Cytometry-NB100-683-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CD68/SR-D1 Antibody (KP1) [NB100-683] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD68/SR-D1 Antibody [KP1] (NB100-683) at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunocytochemistry-Immunofluorescence-NB100-683-img0012.jpg)
![Western Blot: CD68/SR-D1 Antibody (KP1) [NB100-683] - Total protein from mouse Raw cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-CD68 (NB100-683) in blocking buffer and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Western-Blot-NB100-683-img0007.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (KP1) [NB100-683] - An intracellular stain was performed on A431 cells with CD68/SR-D1 [KP1] Antibody NB100-683AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Flow-Cytometry-NB100-683-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD68/SR-D1 Antibody (KP1) [NB100-683] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD68/SR-D1 Antibody [KP1] conjugated to Alexa Fluor 647 (NB100-683AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunocytochemistry-Immunofluorescence-NB100-683-img0011.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (KP1) [NB100-683] - Analysis of a FFPE tissue section of human spleen using 1:200 dilution of CD68 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunohistochemistry-Paraffin-NB100-683-img0006.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (KP1) [NB100-683] - An intracellular stain was performed on THP-1 cells with CD68 Antibody [KP1] NB100-683 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Flow-Cytometry-NB100-683-img0005.jpg)
![Dual RNAscope ISH-IHC: CD68/SR-D1 Antibody (KP1) [NB100-683] - NOS2 mRNA (red) and CD68 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-NOS2 and CD68/SR-D1 antibody (KP1) at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Dual-RNAscope-ISH-IHC-NB100-683-img0010.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Mouse spleen stained with FoxP3 antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0011.jpg "Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Mouse spleen stained with FoxP3 antibody. IHC-P image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Number of Granzyme B+ and FoxP3+ cells infiltrating tumors. Representative images of IHC staining of FoxP3+ and Granzyme B+ cells in the peri-tumoral areas in two mice characterized by low FoxP3+ and high Granzyme B+ (panels 1 and 2) or high FoxP3+ and low Granzyme B+ (panels 3 and 4). Image collected and cropped by Citeab from the following publication (Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget (2018) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0025.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB100-39002] - CCR10-expressing CD4+CD25+FOXP3+ Treg cells are enriched in the spinal cord after SCI. Double immunostaining of FOXP3 (red) and CCR10 (green) in the spinal cord sections after sham or SCI surgery. The merged images are also shown. Arrows indicate cells with positive staining and colocalization. Scale bar, 100 i1/4m. Data are mean A+- SD. Image collected and cropped by Citeab from the following publication (CCL28 promotes locomotor recovery after spinal cord injury via recruiting regulatory T cells. Aging (Albany NY) (2019) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB100-39002-img0027.jpg)
![Flow Cytometry: FoxP3 Antibody [NB100-39002] - An intracellular stain was performed on SK-MEL-28 cells with NB100-39002 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB100-39002-img0022.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Tissue section of human tonsil using 1:200 dilution of rabbit anti-FoxP3 antibody. The staining was developed with HRP-labeled anti-rabbit IgG secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. This FoxP3 antibody generated an expected and a specific nuclear staining of FOXP3 in a subset of cells which are potentially the Treg cells.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0017.jpg)
![Immunohistochemistry: FoxP3 Antibody [NB100-39002] - Antibody was tested in mouse spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-NB100-39002-img0014.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - FFPE bovine spleen tissue. Deparaffinization and antigen retrieval was carried out with PTlink from Dako, citrate buffer pH 6. Anti-Foxp3 antibody was used at a 1:100 dilution. Secondary reagent: Envision, from Dako. Staining: DAB and hematoxylin. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0024.jpg)
![Western Blot: FoxP3 Antibody [NB100-39002] - Jurkat Tag cells were transfected with the expression vector (vector) or with the Foxp3 expression construct (Foxp3). 24 hours after transfection, cells were lysed and analyzed by Western blot with anti-Foxp3 antiserum (1:2000 dilution).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Western-Blot-NB100-39002-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: FoxP3 Antibody [NB100-39002] - Transfectants were stained with anti-Foxp3 antibody and HRPO-conjugated (upper panel) or Cy3-conjugated (lower panels) secondary antibody. Representative images (x100) are shown.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunocytochemistry-Immunofluorescence-NB100-39002-img0012.jpg)
![Immunohistochemistry-Paraffin: FoxP3 Antibody [NB100-39002] - Tissue section of human tonsil using 1:200 dilution of rabbit anti-FoxP3 antibody. The staining was developed with HRP-labeled anti-rabbit IgG secondary antibody and DAB reagent, and nuclei of cells were counterstained with hematoxylin. This FoxP3 antibody generated an expected and a specific nuclear staining of FOXP3 in a subset of cells which are potentially the Treg cells.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Immunohistochemistry-Paraffin-NB100-39002-img0015.jpg)
![Flow Cytometry: FoxP3 Antibody [NB100-39002] - Transfectants were permeabilized and stained with anti-Foxp3 antibody and FITC-conjugated secondary antibody. Cells were analyzed by flow cytometry. Percentage of positively stained cells are shown.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB100-39002-img0013.jpg)
![Flow Cytometry: FoxP3 Antibody [NB100-39002] - An intracellular stain was performed on MCF7 cells with FoxP3 Antibody NB100-39002PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/FoxP3-Antibody-Flow-Cytometry-NB100-39002-img0021.jpg)
![Dual RNAscope ISH-IHC: FoxP3 Antibody [NB100-39002] - CD8A mRNA (red) and FOXP3 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD8A and FoxP3 antibody at 1:400 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Dual-RNAscope-ISH-IHC-NB100-39002-img0028.jpg)
![Dual RNAscope ISH-IHC: FoxP3 Antibody [NB100-39002] - CD4 mRNA (red) and FOXP3 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CD4 and FOXP3 antibody at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/FoxP3-Antibody-Dual-RNAscope-ISH-IHC-NB100-39002-img0029.jpg)
![Immunocytochemistry/ Immunofluorescence: FoxP3 Antibody - BSA Free [NB100-39002] - CCR10-expressing CD4+CD25+FOXP3+ Treg cells are enriched in the spinal cord after SCI. (A, B) Representative flow cytometry dot plots (A) & percentage (B) of CD4+CD25+FOXP3+ cells among the CD4+ T cells in the spinal cord after sham or SCI surgery. Cells were gated on 7-AAD negative population & the numbers inside plots refer to % Treg cells (n=5). (C, D) Representative histogram of CCR10 (C) & CCR3 (D) expression in CD4+CD25+FOXP3+ cells as gated in (A). (E) CD4+CD25+FOXP3+ cells in the spinal cord from sham & SCI mice were sorted out & analyzed by Western blotting to detect the expression of CCR10 & CCR3. GAPDH was used as a loading control. (F) Double immunostaining of FOXP3 (red) & CCR10 (green) in the spinal cord sections after sham or SCI surgery. The merged images are also shown. Arrows indicate cells with positive staining & colocalization. Scale bar, 100 μm. Data are mean ± SD. The statistical analysis was performed using Student’s t-test. **, P<0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31557129), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-39002_rabbit-polyclonal-foxp3-antibody-310202415541911.jpg)
![Immunocytochemistry/ Immunofluorescence: FoxP3 Antibody - BSA Free [NB100-39002] - Effects of anaphylatoxins on transcription factor phosphorylation in ARPE-19 cells. (A–C) Protein phosphorylation of (A) CREB (Ser133); (B) FoxP3 (Ser418); & (C) FOXO1 (Ser256) was examined in ARPE-19 cells treated with C3a, C5a, or the combination of C3a/C5a at 1, 5, 10, & 15 min. Phosphorylation levels were normalized to beta -actin (relative p-protein levels), & slopes of the time course were determined. Anaphylatoxins were applied at concentrations of 300 nM (C3a) & 50 nM (C5a). Data are mean + SEM, n = 3, *p < 0.05, ***p < 0.001 (Student’s t-test). (D) Immunofluorescence staining of FoxP3. Upper panel: Lewis rat (albino) eye with experimental uveitis; lower panel: normal rat eye. Asterisks mark immune cells infiltrating the retina from the choroid through the retinal pigment epithelium (RPE) in the eye with uveitis (clinical score of 2, histological score of 1). Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fimmu.2017.00703/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-39002_rabbit-polyclonal-foxp3-antibody-31020241554547.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0005.jpg "Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.")
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Expression of TLR2 was determined by western blotting. The immunoreactivity of the anti-TLR2 was confirmed with human intestinal lysate. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0015.jpg)
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Total protein from human THP-1 and U937 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TLR2 (NB100-56722) in 5% BSA-TBST and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0016.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Monitoring of TLR2 expression in normal B cells and primary MCL cells cultured for 24h in the absence/presence of CD40L, IL-4, and TLR ligands. Filled curves refer to isotypic control, empty curves to the TLR2 antibody (NB100-56722) of untreated samples. Dotted histograms represent CD40L+IL4 activated cells, dashed curves indicate CD40L+IL4 activated cells further treated with TLR ligands. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0153823) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0013.jpg)
![Flow (Cell Surface): TLR2 Antibody (TL2.1) [NB100-56722] - Flow (Cell Surface): - Azide Free [NB100-56726] - Analysis using the PE conjugate of NB100-56726. Staining of TLR2 on stable transfected cell line using this antibody at 1 ug/10^6 cells. Green: isotype control. Red: anti-TLR2 antibody. Image using the Azide Free form of this antibody.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cell-Surface-NB100-56722-img0010.jpg)
![Block/Neutralize: TLR2 Antibody (TL2.1) [NB100-56722] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR2 antibody (NB100-56722) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Block-Neutralize-NB100-56722-img0014.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) - BSA Free [NB100-56722] - Intracellular flow analysis of TLR2 in 1x10^6 PBMCs using 2 ug of NB100-56722. Shaded histogram represents cells without antibody; green represents isotype control; purple represents anti-TLR2 antibody.](http://images.novusbio.com/fullsize/nb100-56722_mouse-monoclonal-tlr2-antibody-tl2-1-17720241003212.jpg)
![Western Blot: IKK beta Antibody (10AG2) [NB100-56509] - Representative western blot of IKKB (E) in monocytes with quantification on the right. All data are representative of 5 separate experiments. Unpaired student t-test. ***p < 0.001. Image collected and cropped by CiteAb from the following publication (doi.org/10.3389/fimmu.2020.01478) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Western-Blot-NB100-56509-img0015.jpg "<b>Biological Strategies Validation. </b>Western Blot: IKK beta Antibody (10AG2) [NB100-56509] - Representative western blot of IKKB (E) in monocytes with quantification on the right. All data are representative of 5 separate experiments. Unpaired student t-test. ***p < 0.001. Image collected and cropped by CiteAb from the following publication (doi.org/10.3389/fimmu.2020.01478) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: IKK beta Antibody (10AG2) [NB100-56509] - Analysis of IKK beta Antibody in HeLa cells. Antibody dilution 5 ug/ml. Image from verified customer review.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Immunocytochemistry-Immunofluorescence-NB100-56509-img0016.jpg)
![Immunohistochemistry-Paraffin: IKK beta Antibody (10AG2) [NB100-56509] - Analysis of a FFPE tissue section of human placenta using 1:200 dilution of IKK beta clone 10AG2 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Immunohistochemistry-Paraffin-NB100-56509-img0014.jpg)
![Flow Cytometry: IKK beta Antibody (10AG2) [NB100-56509] - Analysis of PE conjugate of NB100-56509. An intracellular stain was performed on Jurkat cells with IKK Beta antibody (10AG2) NB100-56509PE (blue) and a matched isotype control NBP2-27287AF488 (orange). Cells were fixed with 4% PFA and then permeablized wi](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Flow-Cytometry-NB100-56509-img0012.jpg)
![Western Blot: IKK beta Antibody (10AG2) [NB100-56509] - Analysis of A) human Daudi, B) HeLa, and C) mouse NIH3T3 lysate probed with IKKbeta antibody at 2 ug/ml.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Western-Blot-NB100-56509-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: IKK beta Antibody (10AG2) [NB100-56509] - U-87 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton-X100. The cells were incubated with anti-IKK beta Antibody (10AG2) at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Immunocytochemistry-Immunofluorescence-NB100-56509-img0013.jpg)
![Flow Cytometry: IKK beta Antibody (10AG2) [NB100-56509] - Analysis using the Alexa Fluor (R) 488 conjugate of NB100-56509. Staining of IKKbeta in HEK 293 cells using 0.1 ug of Alexa Fluor 488-conjugated antibody. Green histogram represents the isotype control , red represents the IKKbeta antibody.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Flow-Cytometry-NB100-56509-img0010.jpg)
![Flow Cytometry: IKK beta Antibody (10AG2) [NB100-56509] - Analysis using Alexa Fluor (R) 647 conjugate of NB100-56509. An intracellular stain was performed on HeLa cells with IKK beta antibody (10AG2) NB100-56509 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. 1 ug of antibody was added to 100 uL of staining buffer and cells were incubated for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Flow-Cytometry-NB100-56509-img0011.jpg)
![Simple Western: IKK beta Antibody (10AG2) [NB100-56509] - Lane view shows a specific band for IKK beta in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/IKK-beta-Antibody-10AG2-Simple-Western-NB100-56509-img0008.jpg)
![Western Blot: IKK beta Antibody (10AG2) - BSA Free [NB100-56509] - TRAM is required for the pro-inflammatory polarization of macrophages by SLD-LPS. (A,B) Flow cytometry analysis of Ly6C (A) or CD200R (B) expression in WT or TRAM−/− live-cell-gated macrophages with geometric MFI quantification on right. Pink = PBS, Blue = 100 pg/ml LPS. (C–E) Representative Western blots of IKK-beta (C), p-p65 (D), & total NF-kappa B p65 (E) expression in WT & TRAM−/− monocytes treated with either PBS or 100 pg/mL LPS for 5 days. Quantification is depicted on the right. (F) Ratio of p-p65/total p65 (p-p65 levels from (D) divided by corresponding total p65 levels). All data are representative of at least 3 separate experiments (n = 3) for (A,B) & n = 6 for (C–F). ANOVA with Tukey's multiple comparisons test (A,B); unpaired student t-test (C–F) *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s, non-significant; MFI, Mean fluorescence intensity. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32765513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56509_mouse-monoclonal-ikk-beta-antibody-10ag2-31020241554520.jpg)
![Immunohistochemistry: CD4 Antibody [NBP1-19371] - Increased CD3+ and CD4+ T-cell occurrence in the brainstem of SHR-72 transgenic rat model for tauopathies. (A-D) Immunofluorescence staining showed CD4+ T-cells in SHR-72 transgenic animals. (E- H) Immunofluorescence staining showed more perivascular than brain parenchyma infiltrating CD4+ T-cells in SHR-72 transgenic animals. PLoS One. 2019 May 23;14(5):e0217216. doi: 10.1371/journal.pone.0217216.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-NBP1-19371-img0017.jpg "Immunohistochemistry: CD4 Antibody [NBP1-19371] - Increased CD3+ and CD4+ T-cell occurrence in the brainstem of SHR-72 transgenic rat model for tauopathies. (A-D) Immunofluorescence staining showed CD4+ T-cells in SHR-72 transgenic animals. (E- H) Immunofluorescence staining showed more perivascular than brain parenchyma infiltrating CD4+ T-cells in SHR-72 transgenic animals. PLoS One. 2019 May 23;14(5):e0217216. doi: 10.1371/journal.pone.0217216.")
![Immunohistochemistry: CD4 Antibody [NBP1-19371] - DBZ inhibits the accumulation of CD4+ T cells and Th2 differentiation in the AAAs. (B) The representation of immunohistochemical staining for CD4+ in abdominal aorta from four groups (left). Bar graphs show the percentage of CD4+ positive cell areas (right; n=3 per group). Bar: 50 um.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-NBP1-19371-img0018.jpg)
![Western Blot: CD4 Antibody [NBP1-19371] - CD4 antibody was tested in the following cell lysates: 1) human spleen 2) human tonsil 3) human placenta 4) human kidney 5) human liver 6) mouse spleen 7) mouse placenta 8) rat placenta.](http://images.novusbio.com/fullsize/CD4-Antibody-Western-Blot-NBP1-19371-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CD4 Antibody [NBP1-19371] - CD4 antibody was tested in Jurkat cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/CD4-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19371-img0005.jpg)
![Flow Cytometry: CD4 Antibody - BSA Free [NBP1-19371] - An intracellular stain was performed on U-251 MG cells with CD4 Antibody NBP1-19371AF594 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/CD4-Antibody---BSA-Free-Flow-Cytometry-NBP1-19371-img0023.jpg)
![Western Blot: CD4 Antibody [NBP1-19371] - Mouse spleen, 25ug total protein. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-Western-Blot-NBP1-19371-img0007.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Staining of paraffin-embedded mouse brain tissue. Photo courtesy of product review by verified customer.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0006.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Analysis of a FFPE tissue section of mouse brain using CD4 antibody at 1:300 dilution with HRP-DAB detection and hematoxylin counterstaining. The antibody primarily generated a strong signal in the membranes of a subset of cells in the tested section.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0011.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Analysis of a FFPE section of mouse spleen using CD4 antibody at 1:300 dilution with HRP-DAB detection and hematoxylin counterstaining. The antibody generated a strong signal in the membranes of a subset of cells in the spleen section and the staining showed punctate appearance in some cells.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0012.jpg)
![Immunohistochemistry-Frozen: CD4 Antibody [NBP1-19371] - Staining in mouse liver tissue.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Frozen-NBP1-19371-img0013.jpg)
![Immunohistochemistry-Paraffin: CD4 Antibody [NBP1-19371] - Alcohol-fixed paraffin-embedded rat spleen tissue. Dilution 1:150. Image from verified customer review.](http://images.novusbio.com/fullsize/CD4-Antibody-Immunohistochemistry-Paraffin-NBP1-19371-img0014.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on Jurkat cells with CD4 Antibody NBP1-19371R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0015.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on Jurkat cells with CD4 Antibody NBP1-19371AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0016.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on U937 cells with CD4 Antibody NBP1-19371AF594 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0021.jpg)
![Flow Cytometry: CD4 Antibody [NBP1-19371] - An intracellular stain was performed on U937 cells with CD4 Antibody NBP1-19371G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CD4-Antibody-Flow-Cytometry-NBP1-19371-img0022.jpg)
![Simple Western: CD4 Antibody [NBP1-19371] - Lane view shows a specific band for CD4 in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD4-Antibody-Simple-Western-NBP1-19371-img0009.jpg)
![Dual RNAscope ISH-IHC: CD4 Antibody [NBP1-19371] - IFNG mRNA (red) and CD4 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-IFNG and CD4 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin (Cat. No. DS9800), BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD4-Antibody-Dual-RNAscope-ISH-IHC-NBP1-19371-img0019.jpg)
![Dual RNAscope ISH-IHC: CD4 Antibody [NBP1-19371] - CCR5 mRNA (red) and CD4 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-CCR5 and CD4 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD4-Antibody-Dual-RNAscope-ISH-IHC-NBP1-19371-img0020.jpg)
![Immunocytochemistry/ Immunofluorescence: CD4 Antibody - BSA Free [NBP1-19371] - Rats with mild liver damage show immune cells infiltration in cerebellum at 4 weeks, which is prevented by rifaximin. Analysis of immune cells infiltration in cerebellum was performed at 4 weeks by immunohistochemistry using antibodies against (A) CD4, a marker of T lymphocytes (F(3,8) = 4.511, p < 0.01) & (B) IBA1, a marker of meningeal & perivascular macrophages (K-W(4,10) = 27.76, p < 0.0001). (C) Double immunofluorescence with anti-CD4 & anti-CX3CR1 as markers of autoreactive CD4+CD28− T lymphocytes was performed & quantified (K-W(4,5) = 8.711, p < 0.05). (D) Double immunofluorescence with anti-CD4 & anti-CCR6 as marker of Th17 lymphocytes was performed & quantified (K-W(4,7) = 8.858, p < 0.05). Number of animals in each group was added under group names. One-way ANOVA with Tukey’s test (CD4+) & nonparametric Kruskal–Wallis (K-W statistic) with Dunn’s test (Iba1, CD4+/CX3CR1+ & CD4+/CCR6+) was performed to compare all groups. Values significantly different from control rats are indicated by asterisks & from CCl4 rats by a. * p < 0.05, a p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34440206), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-19371_rabbit-polyclonal-cd4-antibody-310202416163759.jpg)
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Intracellular expression of TLR8 in monocyte-derived macrophages (MDMs). MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry. Representative profiles were similar in four independent experiments (n=4 subjects). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0018.jpg "Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Intracellular expression of TLR8 in monocyte-derived macrophages (MDMs). MDMs which were incubated with PE-conjugated anti-TLR8 or isotype antibody control. Intracellular expression was determined by flow cytometry. Representative profiles were similar in four independent experiments (n=4 subjects). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.")
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - Expression of TLR8 in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry. HCMLs were stained using an intracellular staining protocol with TLR8 antibodies followed by relevant secondary fluorescent-conjugated antibodies. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR8. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0021.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: TLR8 Antibody (44C143) [NBP2-24917] - All the cell lines expressed mRNA for TLR8 (Figure 1) and displayed a strong expression of TLR8 protein (Figure 2). Lysates of human intestinal tissue and mouse splenocytes were used as positive controls. Beta-actin was served as loading control and was used to normalize expression levels between cells. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Western-Blot-NBP2-24917-img0022.jpg)
![Immunohistochemistry-Paraffin: TLR8 Antibody (44C143) [NBP2-24917] - Formalin-fixed, paraffin-embedded human spleen stained with TLR8 antibody at 2 ug/ml.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Immunohistochemistry-Paraffin-NBP2-24917-img0005.jpg)
![Flow Cytometry: TLR8 Antibody (44C143) [NBP2-24917] - HEK cells expressing TLR8 were treated with ssRNA40-Alexa 546 followed by fixation, permeablization and staining for TLR8 using anti-TLR8 Alexa 488 conjugate or isotype control IgG1/Kappa Alexa 488. TLR8 detection is shown along the horizontal axis, and ssRNA40 Alexa 546 detection is shown along the vertical axis. Direct excitation (488 and 561 nm lasers) of both fluorophores (Alexa 488 and Alexa 546) allowed quantitation of cells staining positive for TLR8 (anti-TLR8-Alexa488) and cells that had taken up ssRNA40-Alexa 546. Single-stranded RNA40 binds TLR8 (flow cytometry FRET assay). A representative experiment is shown from three independent experiments with similar results. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Flow-Cytometry-NBP2-24917-img0019.jpg)
![Western Blot: TLR8 Antibody (44C143) [NBP2-24917] - Analysis of TLR8 in human Ramos cell lysate. Goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Western-Blot-NBP2-24917-img0006.jpg)
![Simple Western: TLR8 Antibody (44C143) [NBP2-24917] - Simple Western lane view shows a specific band for TLR8 in 0.5 mg/ml of Ramos (left) and Human Spleen (right) lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody Image from the standard format of this antibody.](http://images.novusbio.com/fullsize/TLR8-Antibody-44C143-Simple-Western-NBP2-24917-img0023.jpg)
![Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Flow-Cytometry-NB100-77417-img0004.jpg "Flow Cytometry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of CD45 (30F11) in freshly isolated mouse (Balb C) splenocytes (1x10^6) were stained with [NB100-77417] at 1:1000 dilution and detected with FITC conjugated donkey anti-rat IgG secondary (orange). Shown with rat IgG isotype control (blue).")
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Analysis of FFPE section of mouse spleen using rat monoclonal CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The antibody generated an expected membrane staining in the red and white pulp spleenocytes of the tested spleen section.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0006.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Mouse glomeruli stained with CD45 antibody. 4% formaldehyde fixed paraffin sections. EDTA was used for antigen retrieval. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0013.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a FFPE embedded tissue section of mouse liver using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. The signal was developed using AEC reagent based method with hematoxylin counterstaining.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0003.jpg)
![Immunohistochemistry-Frozen: CD45 Antibody (30-F11) [NB100-77417] - Analysis of a mouse spleen cryosection using CD45 antibody (30-F11) [NB100-77417] at 1:50 dilution. The signal was detected using goat anti-rat Alexa fluor 488 secondary with DAPI counterstaining. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Frozen-NB100-77417-img0008.jpg)
![Immunohistochemistry-Paraffin: CD45 Antibody (30-F11) [NB100-77417] - Staining of a FFPE mouse liver tissue section using 1:100 dilution of CD45 antibody (30-F11) [NB100-77417]. Signal was detected using AF488 conjugated donkey anti-rat secondary antibody at 1:500 dilution. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-Paraffin-NB100-77417-img0002.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0009.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - Severe apoptosis and pathology in the orally infected heart. Experimental design is as outlined in Fig. 1B. Heart sections from moribund mice were examined with H&E, and immunohistochemistry staining for pan-leukocyte infiltration using an anti-CD45 antibody. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0012.jpg)
![Immunohistochemistry: CD45 Antibody (30-F11) [NB100-77417] - VP1-positive infiltrating M2 macrophage and VP1-positive pneumocytes were detectable in the orally infected lung. Adjacent lung sections were examined with H&E and IHC staining for a pan-leukocyte marker CD45. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47455-3), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-30-F11-Immunohistochemistry-NB100-77417-img0011.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of FFPE tissue section of normal human skin using 5 ug/ml concentration of TLR5 antibody (clone 19D759.2). Intense membrane staining of TLR5 was observed specifically in the pigmented basel cells of epidermal layer [10X Magnification]](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0005.jpg "Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of FFPE tissue section of normal human skin using 5 ug/ml concentration of TLR5 antibody (clone 19D759.2). Intense membrane staining of TLR5 was observed specifically in the pigmented basel cells of epidermal layer [10X Magnification]")
![<b>Biological Strategies Validation. </b>Flow Cytometry: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis using the PE conjugate of NBP2-24787. Staining of CD14-/CD83+/TLR5+ diffferentiated myeloid dendritic cells (mDCs). PBMCs were stimulated 5 days with GM-CSF+IL4 prior to the staining. The cells were stained for surface markers CD14 and CD83 FITC, and TLR5 PE. CD14- cells were gated and stained with PE-conjugated isotype control (mouse IgG2a), and FITC-conjugated CD83 (left). CD14- cells were gated and stained with 1 ug PE-conjugated TLR5 , and FITC-conjugated CD83 (right).](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Flow-Cytometry-NBP2-24787-img0011.jpg)
![Western Blot: TLR5 Antibody (19D759.2) [NBP2-24787] - BEAS-2B cells whole cell lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Western-Blot-NBP2-24787-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TLR5 Antibody (19D759.2) [NBP2-24787] - Staining using in-vitro cultured fixed non-permeabilized MCF7 breast cancer cells (ATCC). EpCAM (cell membrane) staining is represented in green (FITC filter), nuclei staining is represented in blue (DAPI filter). Image from a verified customer review using the Alexa Fluor 488 conjugated format of this antibody.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunocytochemistry-Immunofluorescence-NBP2-24787-img0012.jpg)
![Immunohistochemistry: TLR5 Antibody (19D759.2) [NBP2-24787] - TLR5 and TLR7 expression in nasopharyngeal carcinoma and in the normal epithelium. Mild positive TLR5 expression in NK-U. Strong positive TLR5 expression in KSCC. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5816-9), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-NBP2-24787-img0013.jpg)
![Flow Cytometry: TLR5 Antibody (19D759.2) - BSA Free [NBP2-24787] - Flow analysis of TLR5 in mouse MC38 cells. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-BSA-Free-Flow-Cytometry-NBP2-24787-img0014.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Human skin stained with TLR5 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0004.jpg)
![Immunohistochemistry-Paraffin: TLR5 Antibody (19D759.2) [NBP2-24787] - Analysis of TLR5 in FFPE mouse brain tissue using TLR5 antibody at 5 ug/ml.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Immunohistochemistry-Paraffin-NBP2-24787-img0002.jpg)
![Flow Cytometry: TLR5 Antibody (19D759.2) [NBP2-24787] - Intracellular flow analysis of TLR5 in human monocytes using 0.5 ug of TLR5 antibody. Shaded histogram represents cells without antibody; green represents isotype control; red represents TLR5 antibody. this antibody secondary antibody was used in this test.](http://images.novusbio.com/fullsize/TLR5-Antibody-19D759-2-Flow-Cytometry-NBP2-24787-img0003.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0012.jpg "Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Immunoblot of FPR2 protein in various parts of the rat brain including olfactory bulb (OB), prefrontal cortex (PFC), primary somatosensory cortex (CTX1), parietal association cortex and secondary auditory cortex (CTX2), striatum (STR), thalamus and hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord [SC(C)], thoracic spinal cord [SC(T)], and lumbar spinal cord [SC(L)]. Blots incubated with antigen-absorbed antibody i. e. peptide competition, show reduced band intensities. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Mouse J774A.1, mouse reticulum cell sarcoma macrophage cell line. Left panel is + Anti-Rabbit FITC; middle panel indicates the cell nuclei stained with Hoechst; the right panel is a merged image. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0008.jpg)
![Immunohistochemistry-Paraffin: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - SPM receptors differentially expressed on endothelium and infiltrating leukocytes AE](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NLS1878-img0011.jpg)
![Flow Cytometry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Flow Cytometry: [Alexa Fluor® 700] [NLS1878AF700] - Mouse splenocytes. Cells were pre-gated with live/dead and FSC-A/W to exclude dead cells and cell doublets. Image from verified customer review. Image using the Alexa Fluor 700 form of this antibody.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Flow-Cytometry-NLS1878-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Murine neutrophils were extracted from the bone marrow of C57BL/6 mice and exposed to normal glucose (90 mg/dl) or high glucose (300 mg/dl) and the expression of FPR2 was assessed by western blotting after 1, 2, or 3 hr exposure to glucose. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35112667/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2 Antibody - BSA Free-Western Blot-NLS1878-img0013.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in HL-60 cell lysate.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Western-Blot-NLS1878-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Antibody was tested in Raw264.7 cells with DyLight 488 (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NLS1878-img0005.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Analysis in human kidney cancer using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Immunohistochemistry-NLS1878-img0006.jpg)
![Electron Microscopy: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c=50A nm, e=100A nm. Image collected and cropped by Citeab from the following publication (Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth. Neurochem Res (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FPRL1-FPR2-Antibody---BSA-Free-Electron-Microscopy-NLS1878-img0010.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382420.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534335.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-31020241534380.jpg)
![Immunohistochemistry: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Electron micrographs of FPR2 immunostained sections from the prefrontal cortex. a, b Immunostaining is mostly present in axon pre-terminals (PrT) that did not form synapses with postsynaptic structures. c Occasional axon terminals (AT) are observed to form asymmetrical, putatively glutamatergic synapses (S) with unlabelled dendrites (DE). d Occasional labelled dendrites (DE) are also found, that formed asymmetrical synapses (S) with unlabelled axon terminals (AT). Scale: a, b, c = 50 nm, e = 100 nm Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29948727), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202415382435.jpg)
![Immunocytochemistry/ Immunofluorescence: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Lipoxin A4, along with its precursors & ligand, were altered by hAECs. (A): Expression of the lipoxin A4 precursor genes ALOX‐5, ‐12, & ‐15 was increased at days 5 & 7 compared with saline controls (ALOX‐5: 0.393 ± 0.114 vs. 3.777 ± 1.98; ALOX‐12: 0.484 ± 0.248 vs. 1.520 ± 0.203; ALOX‐15: 0.020 ± 0.007 vs. 1.998 ± 0.983). ∗, p < .05. (B): Lipoxin A4 protein levels were elevated in lung lysates at day 7 in animals treated with hAECs compared with controls (0.103 ± 0.021 ng/ml vs. 0.249 ± 0.072 ng/ml, respectively). ∗, p < .05. (C): At day 7, bleomycin challenge resulted in positively stained F4/80/FPR2 cells, which were was elevated in mice treated with hAECs compared with control mice (5.720% ± 0.587% vs. 8.795% ± 0.687%, respectively). ∗, p < .05. (D): Representative images of F4/80‐ & FPR2‐positive‐stained lung sections from hAEC‐treated animals. Magnification: ×200. Scale bar =100 μm. Abbreviations: DAPI, 4′,6‐diamidino‐2‐phenylindole; FPR2, N‐formyl peptide receptor 2; hAEC, human amnion epithelial cell. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28371562), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-310202416114742.jpg)
![Western Blot: FPRL1/FPR2 Antibody - BSA Free [NLS1878] - Higher expression of Fpr2 in the livers of female mice is related with hepatocyte protection.a qRT-PCP analysis for Fpr2 expression in primary hepatocytes (pHEPs) from WT (male n = 2, female n = 2) & KO mice (male n = 2, female n = 2). Total eight mice were employed in each hepatocyte isolation, & the experiments were replicated at least three times & the mean ± S.E.M. results are graphed (*p < 0.05, **p < 0.005 vs WT male-pHEPs). b Western blot analysis & c double immunofluorescent images of Fpr2 (red) with albumin (green) in these cells. Gapdh was used as internal control. DAPI (blue) was used as nuclear counterstaining. Data shown represent one of three experiments with similar results (Scale bar, 20 μm). d qRT-PCR analysis for Fpr2 & glucose-6-phosphatase (G6pc) in, e cell viability of, & f western blot analysis of cleaved Caspase-3 & pro Caspase-3 in WT & KO female mice-isolated pHEPs treated with vehicle (Veh) or 250 μM of palmitate (PA). The data shown represent one of three experiments with similar results. The mean ± S.E.M. results obtained from three repetitive experiments are graphed (*p < 0.05, **p < 0.005 vs WT-Veh). Gray circles represent individual data points. See Supplementary Data for statistical details. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35102146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nls1878_rabbit-polyclonal-fprl1-fpr2-antibody-3102024161228.jpg)